Patients in CCR with imatinib mesylate treatment need to be followed carefully to assess for risk of relapse.
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. 1,2 . The resulting BCR/ABL gene has been shown to play a critical role in the pathogenesis of CML [3] [4] [5] . The c-ABL gene product is a tyrosine kinase with tightly regulated activity 6, 7 . The BCR/ABL gene product, p210
BCR/ABL , demonstrates constitutive activation of tyrosine kinase activity with enhanced substrate phosphorylation compared with c-ABL [8] [9] [10] .
Abnormal kinase activity appears to be critical for BCR/ABL induced transformation 8, 11 .
Imatinib mesylate (STI571, Imatinib mesylate) is a 2-phenylaminopyramidine compound which has been demonstrated to be a potent inhibitor of all ABL tyrosine kinases (c-ABL , BCR/ABL and Tel/ABL), as well as the PDGF receptor tyrosine kinase and c-kit tyrosine kinases 12 . Other tyrosine kinases are not significantly inhibited. In preclinical studies, imatinib mesylate demonstrated high levels of activity against BCR/ABL containing cells in vitro and in vivo 13, 14 .
Subsequently phase 1 and phase 2 clinical trials have shown remarkable activity of imatinib mesylate in the treatment of CML [15] [16] [17] . Almost all patients in CP achieve hematological response and a high proportion of patients achieve major and complete cytogenetic responses 17 . The drug
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Although the success of this molecular therapeutic approach represents an exciting advance in targeted cancer therapy, it still needs to be determined whether responses to imatinib mesylate in CML patients will be durable. Recent reports indicate that BCR/ABL transcripts, although significantly reduced, can still be detected in patients in CCR on Imatinib, and that molecular remissions are rare 21, 22 . In patients with CML in AP and BC, relapses are observed even after induction of complete cytogenetic response 18, 19 CD34+ cell enriched populations were selected from MNC using immunomagnetic column separation (Miltenyi Biotech Inc., Auburn, CA).
Progenitor assays:
Colony forming cells. CD34+ cells were plated in semisolid methylcellulose progenitor culture for 14-18 days and assessed for the presence of CFU-GM and BFU-E colonies as previously described 25 .
Long-term culture initiating cells. Cells were plated in LTBMC medium on M2-10B4 murine fibroblast feeders previously subcultured in 24 well plates. Cultures were maintained at 37°C in a humidified atmosphere with 5% CO 2 and fed at weekly intervals by removal of half the medium from the wells and replacement with fresh medium. After 6 weeks all non-adherent and adherent cells were harvested, pooled and plated in methylcellulose progenitor culture and the number of CFC evaluated after 14 days 26 . Reverse transcriptase-polymerase chain reaction (RT-PCR) for BCR/ABL mRNA. A nested PCR approach was used to detect BCR/ABL mRNA in total MNC and CD34+ cells. Total cellular RNA was extracted using Triazol reagent, and cDNA generated by reverse transcription using oligo dT primers. PCR amplification was carried out using primers designed to specifically detect the transcripts from the breakpoint region of the p210 bcr-abl fusion gene. Initially 30 cycles of PCR amplification were carried out using the BCR68 and ABL3 primers ( Table 1 ).
Subsequently a fraction of the first stage product was subjected to an additional 30 cycles of PCR amplification using internal nested primers, BCRfwd and ABLrev. Amplified samples were size separated by gel-electrophoresis, ethidium bromide stained and photographed. In preliminary studies it was established that this assay could reliably detect 1 in Samples were considered to be negative for BCR/ABL if no BCR/ABL product was detected in 4 separate PCR assays.
Real time quantitative RT-PCR (Q-PCR). Q-PCR using TaqMan technology was used to
quantitate BCR/ABL mRNA levels in MNC and CD34+ cells. Total cellular RNA was converted to cDNA by reverse transcription and used as the template for the PCR procedure using primers and probes designed to detect the p210 transcripts of the BCR/ABL fusion gene ( Table 1) 
Statistical analysis.
Differences between groups were evaluated using the Students-t test.
Relationships between two sets of variables were evaluated using linear regression analysis.
RESULTS
Fifteen patients who achieved complete cytogenetic remission (CCR) following imatinib mesylate treatment were studied. CCR was defined as 100% Ph-negative metaphases by conventional cytogenetics, and/or BCR/ABL negative by FISH analysis of bone marrow nucleated cells. Multiple samples were collected at different time points from some patients while in continued CCR. A total of 23 samples were studied. Table 2 and LTCIC were all BCR/ABL-6 months after start of treatment, whereas BCR/ABL+ LTCIC were detected at 9 months.
Thirteen of the 15 patients included in this study were in CCR at last follow up, whereas two (#144, #261) have developed evidence of cytogenetic relapse. These two patients were both in Months on imatinib mesylate % BCR/ABL+ cells A.
B.
